Dr. Bitterman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
University of Minnesota Medical Center
Minneapolis, MN 55455Phone+1 612-624-0999- Is this information wrong?
Education & Training
- Clinical Center at the National Institutes of HealthFellowship, Pulmonary Disease and Critical Care Medicine, 1978 - 1985
- University of ChicagoResidency, Internal Medicine, 1976 - 1978
- Yale School of MedicineClass of 1976
Certifications & Licensure
- IL State Medical License 1977 - Present
- MN State Medical License 1985 - 2021
Awards, Honors, & Recognition
- Elected Member Association of American Physicians, 2000
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Elected Member The American Society for Clinical Investigation, 1994
Publications & Presentations
PubMed
- 3 citationsA scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis.Katherine A. Cummins, Peter B. Bitterman, Daniel J. Tschumperlin, David K. Wood> ;APL Bioengineering. 2021 Nov 16
- 12 citationsA CD44/Brg1 nuclear complex confers mesenchymal progenitor cells with enhanced fibrogenicity in idiopathic pulmonary fibrosis.Libang Yang, Hong Xia, Karen Smith, Adam J Gilbertsen, Daniel Beisang, Jonathan Kuo, Peter B. Bitterman, Craig A. Henke> ;JCI Insight. 2021 May 10
- 9 citationsHyaluronan/CD44 axis regulates S100A4-mediated mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis.Hong Xia, Jeremy Herrera, Karen Smith, Libang Yang, Adam J Gilbertsen, Alexey Benyumov, Emilian Racila, Peter B. Bitterman, Craig A. Henke> ;American Journal of Physiology. Lung Cellular and Molecular Physiology. 2021 Mar 10
- Join now to see all
Grant Support
- ROLE OF FIBROTIC EXTRACELLULAR MATRIX IN GENERATING THE IPF FIBROBLASTNIH/NHLBI2014–2018
- Translational Control Of The Fibroblast Phenotype In IPFNational Heart, Lung, And Blood Institute2009–2012
- Translational Control In IPFNational Heart, Lung, And Blood Institute2008–2011
- Translational State Assay For Human SamplesNational Center For Research Resources2008–2010
- Antifibrotic Drug Discovery In Acute Lung InjuryNational Heart, Lung, And Blood Institute2004–2007
- Molecular Targets For Drug Discovery In IPFNational Heart, Lung, And Blood Institute2003–2006
- SCOR In Acute Lung InjuryNational Heart, Lung, And Blood Institute1994–2003
- Translational Repressors As Therapy For OBNational Institute Of Allergy And Infectious Diseases2001–2002
- Translational Control Of Fibroblast ViabilityNational Heart, Lung, And Blood Institute1999–2002
- Training In Lung ScienceNational Heart, Lung, And Blood Institute1999–2002
- Transgenic Murine Model Of Pulmonary FibrosisNational Heart, Lung, And Blood Institute1996–1999
- Role Of Apoptosis In Lung RepairNational Heart, Lung, And Blood Institute1996–1998
- Training-Pulmonary Cell &Molecular Biology &PhysiologyNational Heart, Lung, And Blood Institute1994–1998
- Mesenchymal Cell Subpopulations In Acute Lung FibrosisNational Heart, Lung, And Blood Institute1987–1991
Hospital Affiliations
- M Health Fairview University of Minnesota Medical CenterMinneapolis, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: